Robert Bissonnette, MD

Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis

Author:: April W. Armstrong, MD, MPH; Robert Bissonnette, MD; Raj Chovatiya, MD, PhD; Tina Bhutani, MD; Philip M. Brown, MD, JD; Anna M. Tallman, PharmD; Kim A. Papp, MD, PhD

The National Psoriasis Foundation (NPF) treatment targets aim to achieve 1% or lower body surface area (BSA) affected after 3...